TEL AVIV, Israel, Feb. 4, 2019 /PRNewswire/ -- BioLineRx Ltd.
(NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company
focused on oncology and immunology, today announced that it has
commenced an underwritten public offering of American Depositary
Shares ("ADSs"), each representing one of its ordinary shares with
each ADS to be sold together in a fixed combination with a warrant
to purchase ADSs. All of the securities in the offering are to be
sold by BioLineRx. The offering is subject to market
conditions, and there can be no assurance as to whether or when the
offering may be completed, or as to the actual size or terms of the
offering.
BioLineRx anticipates using the net proceeds from the proposed
offering for general corporate purposes, which may include, but are
not limited to, working capital and funding clinical trials.
Oppenheimer & Co. Inc. is acting as sole book-running
manager for the offering.
The securities described above will be issued pursuant to a
shelf registration statement (File No. 333-222332) that was
previously filed with, and declared effective by, the Securities
and Exchange Commission ("SEC"). Any offer, if at all, will
be made only by means of a prospectus supplement and accompanying
prospectus forming a part of the effective registration
statement. A preliminary prospectus supplement and
accompanying prospectus related to the offering will be filed with
the SEC and will be available on the SEC's website located at
www.sec.gov. Copies of the preliminary prospectus
supplement and accompanying prospectus may also be obtained, when
available, from Oppenheimer & Co. Inc., Attention: Syndicate
Prospectus Department, 85 Broad Street, 26th Floor, New York, New York 10004, by telephone at
212-667-8055, or by email at EquityProspectus@opco.com.
This press release does not constitute an offer to sell or a
solicitation of an offer to buy nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About BioLineRx
BioLineRx is a clinical-stage biopharmaceutical company focused
on oncology and immunology. The Company in-licenses novel
compounds, develops them through pre-clinical and/or clinical
stages, and then partners with pharmaceutical companies for
advanced clinical development and/or commercialization.
BioLineRx's leading therapeutic candidates are: BL-8040, a
cancer therapy platform, which has successfully completed a Phase
2a study for relapsed/refractory acute myeloid leukemia ("AML") and
is in the midst of a Phase 2b study
as an AML consolidation treatment and has initiated a Phase 3 study
in stem cell mobilization for autologous transplantation; and
AGI-134, an immunotherapy treatment in development for multiple
solid tumors, which has recently initiated a Phase 1/2a study. In
addition, BioLineRx has a strategic collaboration with Novartis for
the co-development of selected Israeli-sourced novel drug
candidates; a collaboration agreement with MSD (known as Merck in
the United States and Canada), on the basis of which the Company is
conducting a Phase 2a study in pancreatic cancer using the
combination of BL-8040 and KEYTRUDA® (pembrolizumab),
and a collaboration agreement with Genentech Inc., a member of the
Roche Group, to investigate the combination of BL-8040 and
Genentech's atezolizumab in several Phase 1b/2 studies for multiple solid tumor indications
and AML.
Various statements in this release concerning BioLineRx's
future expectations constitute "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995. These statements include words such as "may," "expects,"
"anticipates," "believes," and "intends," and describe opinions
about future events. These forward-looking statements involve known
and unknown risks and uncertainties that may cause the actual
results, performance or achievements of BioLineRx to be materially
different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Some of
these risks are: changes in relationships with collaborators; the
impact of competitive products and technological changes; risks
relating to the development of new products; and the ability to
implement technological improvements. These and other factors are
more fully discussed in the "Risk Factors" section of BioLineRx's
most recent annual report on Form 20-F filed with the Securities
and Exchange Commission on March 6,
2018 and BioLineRx's other filings with the Securities and
Exchange Commission. In addition, any forward-looking statements
represent BioLineRx's views only as of the date of this release and
should not be relied upon as representing its views as of any
subsequent date. BioLineRx does not assume any obligation to update
any forward-looking statements unless required by law.